Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics

被引：47

作者：

He, Jin-xue ^{[1
]}

Yang, Chun-hao ^{[2
]}

Miao, Ze-hong ^{[1
]}

机构：

[1] Chinese Acad Sci, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China

[2] Chinese Acad Sci, Dept Med Chem, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China

来源：

ACTA PHARMACOLOGICA SINICA | 2010年 / 31卷 / 09期

基金：

中国国家自然科学基金;

关键词：

poly(ADP-ribose) polymerase inhibitor; DNA repair; BRCA1/2; anticancer agents; homologous recombination; DNA-REPAIR; CATALYTIC FRAGMENT; TELOMERE LENGTH; PARP INHIBITORS; MAMMARY-TUMORS; MUTANT-CELLS; COMBINATION; DEFICIENCY; BREAST; DAMAGE;

D O I：

10.1038/aps.2010.103

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, especially to those with specific defects. With AZD2281 and BSI-201 entering phase III clinical trials, the final application of PARP inhibitors in clinic would come true soon. This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.

引用

页码：1172 / 1180

页数：9

共 67 条

[1] PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase [J].

Amé, JC ;

Rolli, V ;

Schreiber, V ;

Niedergang, C ;

Apiou, F ;

Decker, P ;

Muller, S ;

Hoger, T ;

Murcia, JMD ;

de Murcia, G .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (25) :17860-17868

[2] Targeting assay to study the cis functions of human telomeric proteins:: Evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2 [J].

Ancelin, K ;

Brunori, M ;

Bauwens, S ;

Koering, CE ;

Brun, C ;

Ricoul, M ;

Pommier, JP ;

Sabatier, L ;

Gilson, E .

MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (10) :3474-3487

[3]

ASTRAZENECKA, 2008, Patent No. 2008146035

[4] Molecular basis of ataxia telangiectasia and related diseases [J].

Ball, LG ;

Xiao, W .

ACTA PHARMACOLOGICA SINICA, 2005, 26 (08) :897-907

[5] Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease [J].

Bauer, PI ;

Mendeleyeva, J ;

Kirsten, E ;

Comstock, JA ;

Hakam, A ;

Buki, KG ;

Kun, E .

BIOCHEMICAL PHARMACOLOGY, 2002, 63 (03) :455-462

[6]

Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310

[7] Treating cancer by targeting a weakness [J].

Brody, LC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (09) :949-950

[8] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[9] Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy [J].

Cepeda, Victoria ;

Fuertes, Miguel A. ;

Castilla, Josefina ;

Alonso, Carlos ;

Quevedo, Celia ;

Soto, Manual ;

Perez, Jose M. .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2006, 1 (01) :39-53

[10] NICOTINAMIDE MONONUCLEOTIDE ACTIVATION OF A NEW DNA-DEPENDENT POLYADENYLIC ACID SYNTHESIZING NUCLEAR ENZYME [J].

CHAMBON, P ;

MANDEL, P ;

WEILL, JD .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1963, 11 (01) :39-&

← 1 2 3 4 5 6 7 →